Related Experiment Videos
Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and
Summary
Repeated dopamine D1 receptor agonist treatment caused tolerance in rats, while D2 agonists induced sensitization. This suggests D1 receptor desensitization and D2 receptor involvement in L-DOPA
Area of Science:
- Neuroscience
- Pharmacology
- Neurobiology
Background:
- Daily injections of dopamine (DA) D2 receptor agonists typically induce behavioral sensitization in DA-depleted rats.
- Effects of repeated selective DA D1 receptor agonist treatment are less clear, showing equivocal results.
- Understanding differential D1/D2 receptor agonist effects is crucial for Parkinson's disease and related disorders.
Purpose of the Study:
- To investigate the effects of acute and repeated DA receptor agonist treatments with varying D1/D2 selectivities.
- To assess behavioral responses (rotation) and striatal c-fos activation in unilaterally DA-depleted rats.
- To elucidate the roles of D1 and D2 receptors in drug-induced behavioral changes and neuroadaptations.
Main Methods:
- Rats with unilateral DA depletions received daily treatments for 10 days.
- Treatments included a selective D1 agonist (A-85653), a D2 agonist (quinpirole), a combination, or levodopa (L-DOPA).
- Behavioral rotation and striatal c-fos expression were quantified to assess drug effects.
Main Results:
- A-85653 alone led to behavioral tolerance with repeated administration.
- Quinpirole or L-DOPA alone resulted in behavioral sensitization.
- Combined A-85653 + quinpirole showed increased response magnitude but reduced duration; c-fos activation decreased with repeated treatments despite enhanced rotation for quinpirole + A-85653 and L-DOPA.
Conclusions:
- Repeated D1 receptor stimulation may lead to desensitization.
- Behavioral sensitization from repeated L-DOPA treatment appears to be primarily mediated by the D2 receptor.
- Differential receptor desensitization underlies varied responses to dopaminergic therapies.